Welcome! Login | Register
 

Sharks Fall to Portland, 4-3 in OT—Sharks fall to Portland in OT, 4-3

25 Great Last Minute Local Gifts in Central MA—Still haven’t finished your Christmas shopping? Check out…

John Monfredo: Ted Coghlin: A Dynamic and Caring Hero Who Will Be Missed!—During this holiday season we mourn the passing…

Americans Identifying Race Relations as a Top Issue Sharply Rises According to Gallup Poll—Gallup released results from a new poll on…

Sharks Fall 4-1 On Road to Manchester—Sharks Fall 4-1 to Manchester on the road

Monster Jam ‘Roars’ Into the DCU Center—Monster Jam will be returning to the DCU…

Friday Financial Five – December 19th, 2014—Congress finally approved retroactive individual tax breaks

REPORT: Rondo Trade to Dallas is VERY Close—Celtics on the verge of trading Rondo

Massachusetts Adds 13,500 Jobs in November—The executive Office of Labor and Workforce Development…

RE/MAX New England: Pending Sales in Massachusetts Are Up—RE/MAX of New England's November Monthly Housing Report…

 
 

AG Announces $68.5 Million Settlement with AstraZeneca

Friday, March 11, 2011

 

Attorney General Peter Kilmartin announced today that a $68.5 million dollar settlement has been reached with AstraZeneca Pharmaceuticals.

This settlement, which is the largest ever multi-state consumer protection-based pharmaceutical settlement, is expected to bring $908,838 to the state.

The settlement stems from a complaint alleging that AstraZeneca used deceptive practices to market the antipsychotic drug Seroquel for off-label uses, according to the Attorney General. The company was accused of withholding information on the drug’s dangerous potential side effects, in addition to the negative results of scientific study done that tested the safety of the drug.

“This settlement shows the commitment of this office to protect consumers from deceptive marketing and advertising practices by big pharmaceutical companies,” Kilmartin said.

Company promises changes

AstraZeneca has promised to alter the way that it markets Seroquel, eliminating the misleading practices in question. Along with the $68.5 million payment, under the settlement AstraZeneca must comply with provisions addressing numerous concerns that an extensive 3-year investigation yielded. For example, AstraZeneca must have policies in place to ensure that sales personnel do not promote to health care providers who are unlikely to prescribe Seroquel for an FDA-approved use.

Other states participating in the investigation and settlement were: Florida, Illinois, Arizona, California, Colorado, Connecticut, Delaware, Hawaii, Idaho, Iowa, Kansas, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Missouri, Nebraska, Nevada, New Hampshire, New Jersey, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Dakota, Tennessee, Texas, Vermont, Washington, West Virginia and Wisconsin.
 

 

Enjoy this post? Share it with others.